Edition:
United Kingdom

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

49.14NOK
3:25pm BST
Change (% chg)

kr-0.66 (-1.33%)
Prev Close
kr49.80
Open
kr50.20
Day's High
kr51.60
Day's Low
kr49.00
Volume
59,329
Avg. Vol
211,472
52-wk High
kr95.05
52-wk Low
kr37.26

Chart for

About

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide... (more)

Overall

Beta: --
Market Cap(Mil.): kr4,031.45
Shares Outstanding(Mil.): 49.04
Dividend: --
Yield (%): --

Financials

  NANOV.OL Industry Sector
P/E (TTM): -- 85.91 32.75
EPS (TTM): -5.17 -- --
ROI: -33.62 1.70 14.60
ROE: -33.67 3.17 16.33

NORWEGIAN STOCKS-Down on rate outlook, Scatec drops after share issue

OSLO, June 14 (Reuters) - * Norwegian shares traded down on Thursday * Global markets dented by outlook for higher interest rates and weaker data from China * Oslo's benchmark index fell 0.24 pct, or -2.19 points, to 893.81 points and was up by 10.01 pct year-to-date * The broader Oslo All Share Index was down 0.14 percent * Brent crude futures, a trigger for the oil heavy Oslo Bourse, fell $-0.19 to $76.55 a barrel * Among the biggest firms on the Oslo Bourse, Equinor rose 0.28 pct, Telenor fel

14 Jun 2018

BRIEF-Nordic Nanovector Appoints Tone Kvåle As Interim Chief Executive Officer

* NORDIC NANOVECTOR APPOINTS TONE KVÅLE AS INTERIM CHIEF EXECUTIVE OFFICER

20 Apr 2018

BRIEF-Nordic Nanovector Says Humalutin Has Shown Significant Tumour Uptake

* POSTER REPORTING ANTI -TUMOUR EFFECT OF HUMALUTIN® (177LU-CONJUGATED HUMANIZED ANTI-CD37 ANTIBODY, 177LU-NNV003) IN PRECLINICAL MODELS OF NON-HODGKIN'S LYMPHOMA (NHL) WAS PRESENTED YESTERDAY

16 Apr 2018

Earnings vs. Estimates